Every material Form 8-K aTYR PHARMA INC has filed with the SEC since November 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every aTYR PHARMA INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →